知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

5 records (took 0.013 seconds)

    Murine expression of human IgA Lambda locus
    2.
    发明申请
    Murine expression of human IgA Lambda locus 审中-公开
    人IgA Lambda基因座的鼠表达

    公开(公告)号：US20040231012A1

    公开(公告)日：2004-11-18

    申请号：US10753554

    申请日：2004-01-09

    Applicant: The Babraham Institute

    Inventor： Marianne Bruggemann

    IPC: A01K067/027

    CPC classification number: C12N15/8509 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/0381 ,  C07K16/00 ,  C07K2317/24

    Abstract: In humans, approximately 60% of expressed immunoglobulin light chains are of the Kappa type and 40% of the Lambda type. In mice, there is almost no expression from the Lambda locus and over 95% of light chains are of Kappa type. The present invention discloses, among other things, transgenic mice carrying most of the human Ig Lambda light chain locus in their genome. The resulting mice express light chains with Kappa/Lambda ratio similar to the human ratio. Breeding of HuIg Lamda mice to Kappa-deficient mice also is described, as well as the generation of human monoclonal antibodies from transgenic mice with human Ig Lambda locus.

    Abstract translation: 在人类中，约60％的表达免疫球蛋白轻链是Kappa型和40％的Lambda型。 在小鼠中，几乎没有来自Lambda基因座的表达，超过95％的轻链是Kappa型的。 本发明尤其公开了在其基因组中携带大部分人Ig Lambda轻链基因座的转基因小鼠。 所得到的小鼠以Kappa /λ比率表示与人的比例相似的轻链。 还描述了将HuIg Lamda小鼠育种到Kappa缺陷小鼠，以及用具有人Ig Lambda基因座的转基因小鼠产生人单克隆抗体。

    MIR-155 ENHANCEMENT OF CD8+ T CELL IMMUNITY
    3.
    发明申请
    MIR-155 ENHANCEMENT OF CD8+ T CELL IMMUNITY 审中-公开
    MIR-155增强CD8 + T细胞免疫

    公开(公告)号：US20140120136A1

    公开(公告)日：2014-05-01

    申请号：US14051895

    申请日：2013-10-11

    Applicant: The Babraham Institute ,  Philadelphia Health & Education Corporation d/b/a Drexel University College of Medicine

    Inventor： Peter D. Katsikis ,  Donald T. Gracias ,  Martin Turner

    IPC: C12N15/113

    CPC classification number: C12N15/113 ,  A61K35/17 ,  C12N5/0636 ,  C12N2310/141 ,  C12N2501/65

    Abstract: The present invention provides novel methods of enhancing CD8+ T cell mediated immunity (also referred to as “CD8+ T cell immunity”) in a patient having a diseased state. In particular, the present invention provides for the enhanced expression of miR-155 in a population of patient specific T cells through the introduction of a nucleic acid molecule encoding a miR-155 transcript or a nucleic acid molecule encoding a chimeric antigen receptor and a miR-155 transcript into those cells, followed by the reintroduction of the T cells into the patient. The present invention also provides methods of enhancing the expansion of these T cells relative to control cells. Increased expansion of CD8+ T cells following enhanced miR-155 expression is directly related to enhanced CD8+ T cell immunity. The present invention further provides methods of enhancing anti-cancer immunity in a patient through the increased expression of miR-155 in patient specific T cells.

    Abstract translation: 本发明提供了具有疾病状态的患者中增强CD8 + T细胞介导的免疫（也称为“CD8 + T细胞免疫”）的新方法。 特别地，本发明通过引入编码miR-155转录物的核酸分子或编码嵌合抗原受体和miR的核酸分子来提供miR-155在患者特异性T细胞群体中的增强表达 -155转录到这些细胞中，随后将T细胞重新引入患者体内。 本发明还提供了相对于对照细胞增强这些T细胞的扩增的方法。 增强的miR-155表达后CD8 + T细胞的增加与增强的CD8 + T细胞免疫直接相关。 本发明还提供了通过增加miR-155在患者特异性T细胞中的表达来增强患者抗癌免疫的方法。

Patent Agency Ranking